Trial intelligence / Profile preview

Dasotraline in Children with ADHD (Laboratory Classroom)

NCT02734693Phase 3Completed

Sponsor
Sumitomo Pharma America
Start
Apr 2016
Primary completion
Feb 2017
Modality
Small Molecules
Countries
1
01

Overview

A Phase 3 trial of dasotraline in attention deficit hyperactivity disorder (ADHD), sponsored by Sumitomo Pharma America. Started Apr 2016; status: completed.

02

Drugs

dasotraline
03

Conditions

attention deficit hyperactivity disorder (ADHD)

Beyond the preview

Go deeper on NCT02734693.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT02734693.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call